Recipharm increases API and raw material stocks to ensure supply amid higher antibiotics demand
CDMO says it has made "notable changes" to its supply chain processes to ensure continuing supply of medicines during COVID-19 pandemic
Recipharm has increased stocks of active pharmaceutical ingredients (APIs) and raw materials to ensure continuity of supply and to meet higher antibiotics demand amid the global coronavirus pandemic, the Swedish contract development and manufacturing organisation said on Tuesday.
Antibiotics demand has risen as secondary bacterial infections are common in severely ill patients with COVID-19.
“We are increasing the safety stock of both APIs and raw material and are looking at different shift patterns for the existing team, as well as recruiting more personnel where required,” said Erik Haeffler, Vice President, Manufacturing Services & Head of Sustainability, at Recipharm.
The company has also seen generally higher demand for goods and services to support the fight against COVID-19.
“Naturally, this has put a strain on our supply chain and has affected it in various, but manageable, ways,” he said, adding that the company had made "notable changes" to its supply chain processes to maintain the supply of critical medicines.
Recipharm manufactures antibiotics – which can only be manufactured in dedicated plants with the correct technology and capabilities -- at four of its facilities.
“We are following the government guidelines and implementing the appropriate safety measures to ensure we continue to work efficiently,” Haeffler said.
Delays in both incoming materials and the shipment of its goods have been recent challenges for the company, with suppliers at reduced capacity, and tighter border control restrictions slowing down the transportation of goods.
Despite these issues, Recipharm said it had adjusted well to this “difficult and testing situation” to minimize the impact on the supply chain.
Recipharm added it may already have reached peak demand and predicted that volumes will return to ‘normal’ once the acute state of COVID-19 has passed.
Last week, Recipharm said it had secured supply of the API chloroquine phosphate for its drug Klorokinfosfat RPH Pharma and started manufacturing the product. While chloroquine products are not currently indicated for treatment or prevention of COVID-19, some clinical studies involving chloroquine and hydroxychloroquine have recently been initiated.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance